CAB LA

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ImmunodeficiencyHIVHIV Infections

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

1

Sovaldi

Gilead

Phase 3

22

Repatha

Amgen

Phase 3

13

Retrovir

BBp Consulting, Inc

Phase 3

64

Vemlidy

Gilead

Phase 3

—5

Valtrex

GGlaxo Dba Glaxosmithkline

Phase 3

16

Livalo

MMedicure

Phase 3

17

Truvada

Gilead

Phase 3

28

FTC/TDF

Gilead

Phase 3

19

CAB LA

GSK

Phase 3

510

Biktarvy

GSK

Phase 3

1Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunodeficiency5 trials

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

Completed·GSK·Phase 3·NCT04399551·437 enrolled

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Recruiting·GSK·Phase 3·NCT06134362·3,508 enrolled

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Completed·GSK·Phase 2·NCT02120352·309 enrolled

Show 2 more trials

A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men

Completed·GSK·Phase 1·NCT03422172·48 enrolled

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

Completed·GSK·Phase 2·NCT03639311·97 enrolled

Acceptability2 trials

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04824131·55 enrolled

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04692077·9 enrolled

Tics1 trial

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Active, not recruiting·GSK·Phase 2·NCT06741397·229 enrolled

Safety and Efficacy1 trial

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT03164564·3,224 enrolled

Pregnancy1 trial

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT06336434

6 more indications

Women1 trial

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2/3·NCT02720094·4,570 enrolled

Adult1 trial

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults

Active, not recruiting·GSK·Phase 1·NCT06786520·69 enrolled

ART1 trial

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

Completed·Johnson & Johnson·Phase 1·NCT05112939·126 enrolled

HIV1 trial

CHIPP-PrEP: Cabotegravir-Hormone Interrogation of Pharmacokinetics/Pharmacodynamics (PK/PD) for HIV Prevention

Recruiting·JJohns Hopkins University·Phase 1·NCT07672717·32 enrolled

Infection, Human Immunodeficiency Virus1 trial

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed

Active, not recruiting·GSK·Phase 3·NCT02951052·618 enrolled

HIV Infections1 trial

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents With HIV Who Are Virologically Suppressed on ART

Not yet recruiting·GSK·Phase 3·NCT07650916·564 enrolled

Details

Drug Info

Related News